Literature DB >> 17458702

Growth hormone measurements in the diagnosis and monitoring of acromegaly.

Akira Sata1, Ken K Y Ho.   

Abstract

Before the availability of immunoassays for IGF-I, growth hormone (GH) measurement was the sole method used in the biochemical assessment of acromegaly. IGF-I has since been established as the most reliable biochemical indicator of acromegaly. The last 25 years has seen important advances in the understanding of the neuroregulation and in the characterization of GH secretion in acromegaly. The availability of supersensitive GH has changed many aspects of the interpretation of GH-value in the management of acromegaly. Hypersecretion and abnormal neuroregulation characterize GH secretion in acromegaly. GH can be measured in many ways: as a single random sample, as multiple samples, either spontaneously or as an integral part of a dynamic test. These approaches give useful information on diagnosis, therapy, and prognosis. There is a place for measuring GH in the management of acromegaly although it complements that of IGF-I.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17458702     DOI: 10.1007/s11102-007-0034-x

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   3.599


  55 in total

1.  Basal and glucose-suppressed GH levels less than 1 microg/L in newly diagnosed acromegaly.

Authors:  Pamela U Freda; Carlos M Reyes; Abu T Nuruzzaman; Robert E Sundeen; Jeffrey N Bruce
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

Review 2.  Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human.

Authors:  A Giustina; J D Veldhuis
Journal:  Endocr Rev       Date:  1998-12       Impact factor: 19.871

3.  The influence of octreotide treatment on pulsatile growth hormone release in acromegaly.

Authors:  F Roelfsema; H de Boer; M Frölich
Journal:  Clin Endocrinol (Oxf)       Date:  1990-08       Impact factor: 3.478

4.  Increase of serum growth hormone concentration following thyrotropin-releasing hormone injection in patients with acromegaly or gigantism.

Authors:  M Irie; T Tsushima
Journal:  J Clin Endocrinol Metab       Date:  1972-07       Impact factor: 5.958

Review 5.  Long-term treatment outcome in acromegaly.

Authors:  I M Holdaway; C R Rajasoorya; G D Gamble; A W Stewart
Journal:  Growth Horm IGF Res       Date:  2003-08       Impact factor: 2.372

6.  Somatomedin C in treated acromegaly: poor correlation with growth hormone and clinical response.

Authors:  L D Stonesifer; R M Jordan; P O Kohler
Journal:  J Clin Endocrinol Metab       Date:  1981-11       Impact factor: 5.958

7.  Enhanced basal and disorderly growth hormone secretion distinguish acromegalic from normal pulsatile growth hormone release.

Authors:  M L Hartman; S M Pincus; M L Johnson; D H Matthews; L M Faunt; M L Vance; M O Thorner; J D Veldhuis
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

8.  Pituitary adenomas of patients with acromegaly express thyrotropin-releasing hormone receptor messenger RNA: cloning and functional expression of the human thyrotropin-releasing hormone receptor gene.

Authors:  M Yamada; T Monden; T Satoh; N Satoh; M Murakami; T Iriuchijima; T Kakegawa; M Mori
Journal:  Biochem Biophys Res Commun       Date:  1993-09-15       Impact factor: 3.575

9.  Gender and age in the biochemical assessment of cure of acromegaly.

Authors:  P U Freda; R E Landman; R E Sundeen; K D Post
Journal:  Pituitary       Date:  2001-08       Impact factor: 4.107

10.  Fasting enhances growth hormone secretion and amplifies the complex rhythms of growth hormone secretion in man.

Authors:  K Y Ho; J D Veldhuis; M L Johnson; R Furlanetto; W S Evans; K G Alberti; M O Thorner
Journal:  J Clin Invest       Date:  1988-04       Impact factor: 14.808

View more
  4 in total

Review 1.  Acromegaly pathogenesis and treatment.

Authors:  Shlomo Melmed
Journal:  J Clin Invest       Date:  2009-11-02       Impact factor: 14.808

2.  Gigantism caused by growth hormone secreting pituitary adenoma.

Authors:  Noorisaem Rhee; Kumi Jeong; Eun Mi Yang; Chan Jong Kim
Journal:  Ann Pediatr Endocrinol Metab       Date:  2014-06-30

Review 3.  Growth Hormone/Insulin Growth Factor Axis in Sex Steroid Associated Disorders and Related Cancers.

Authors:  Rachel Bleach; Mark Sherlock; Michael W O'Reilly; Marie McIlroy
Journal:  Front Cell Dev Biol       Date:  2021-03-18

4.  Acromegaly: role of surgery in the therapeutic armamentarium.

Authors:  Gerardo Guinto; Miguel Abdo; Erick Zepeda; Norma Aréchiga; Moisés Mercado
Journal:  Int J Endocrinol       Date:  2012-11-12       Impact factor: 3.257

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.